Nasdaq

Arrowhead price target lowered to $45 from $62 at Piper Sandler

Piper Sandler lowered the firm’s price target on Arrowhead (ARWR) to $45 from $62 and keeps an Overweight rating on the shares. The firm notes Arrowhead entered a strategic partnership with Sarepta ...
Nasdaq

Arrowhead price target raised to $80 from $60 at H.C. Wainwright

H.C. Wainwright analyst Patrick Trucchio raised the firm’s price target on Arrowhead (ARWR) to $80 from $60 and keeps a Buy rating on the shares after the company recently announced a global license ...
Business Insider

Arrowhead price target lowered to $38 from $51 at B. Riley

B. Riley lowered the firm’s price target on Arrowhead (ARWR) to $38 from $51 and keeps a Buy rating on the shares following the fiscal Q1 report. The firm says Ionis Pharmaceuticals’ (IONS) Tryngolza ...
Hosted on MSN

Arrowhead price target raised to $70 from $45 at Piper Sandler

Piper Sandler analyst Edward Tenthoff raised the firm’s price target on Arrowhead (ARWR) to $70 from $45 and keeps an Overweight rating on the shares. The firm notes the FDA approved Arrowhead’s first ...
Hosted on MSN

Arrowhead price target raised to $85 from $80 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Arrowhead (ARWR) to $85 from $80 and keeps a Buy rating on the shares. The firm says the company’s “transformative” fiscal Q4 was driven by FDA ...